Get started
Author

Luciano Latini

Observed names: L Latini, L. Latini
Observed institutions: Università Cattolica del Sacro Cuore, University of Verona, University of Parma, Novartis (Switzerland), University of Trieste, University of L'Aquila, Universitair Ziekenhuis Leuven, Ottawa Hospital, The Royal Free Hospital, Institut Gustave Roussy, University of Chieti-Pescara, Hospital Universitario 12 De Octubre, Fondazione Salvatore Maugeri, Centre Léon Bérard, Azienda Ospedaliera San Gerardo, Ospedali Riuniti Marche Nord, Federico II University Hospital, Duke Medical Center, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Ospedale SS. Annunziata, Kaohsiung Veterans General Hospital, Ospedale "Floraspe Renzetti", Vall d'Hebron Institute of Oncology, Ospedale di Macerata, Pontifícia Universidade Católica do Rio Grande do Sul
OpenAlex ID: A5045839302
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · Sandra M Swain, David Miles, et al. · The Lancet Oncology · 960
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
2012 · T. Pressiani, C. Boni, et al. · Annals of Oncology · 154
PDF
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 119
PDF
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 102
PDF
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
2007 · Annamaria Ruzzo, Emanuele Canestrari, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 61
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
2017 · Jean-François Emile, Catherine Julié, et al. · European Journal of Cancer · 49
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
2015 · E. Van Cutsem, H. Prenen, et al. · Annals of Oncology · 43
PDF
Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence
2014 · Mauro Finicelli, Giovanni Benedetti, et al. · Oncotarget · 40
PDF
KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study
2008 · C. Braconi, R. Bracci, et al. · Annals of Oncology · 33
PDF
Desmoplastic Small Round Cell Tumour: A Description of Two Cases and Review of the Literature
2002 · Paolo Lippe, Rossana Berardi, et al. · Oncology · 24
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer
1996 · A Piga, S Cascinu, et al. · British Journal of Cancer · 21
PDF
Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study
2009 · X. Pivot, S. Verma, et al. · Journal of Clinical Oncology · 17
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
2012 · Francis P. Arena, Shinzaburo Noguchi, et al. · Journal of Clinical Oncology · 16
The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy
2010 · Laura Doni, Alessandra Perin, et al. · Critical Reviews in Oncology/Hematology · 16
Epidermal Growth Factor Receptor Exon 19 Deletions Predict Complete Regression of Multiple Intracranial Metastases in Two Cases of Non-small Cell Lung Cancer Treated with Erlotinib
2009 · Giovanni Benedetti, Luciano Latini, et al. · Journal of Thoracic Oncology · 13
PDF
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting
2017 · Daniele Generali, Filippo Montemurro, et al. · The Oncologist · 11
PDF
Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.
2011 · T. Pressiani, L. Rimassa, et al. · Journal of Clinical Oncology · 9
Synchronous Primary Hepatic Lymphoma and Epidermoid Lung Carcinoma Treated with Chemotherapy and Surgery
1995 · Francesco Graziano, Riccardo Cellerino, et al. · American Journal of Clinical Oncology · 9
Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors
2015 · Barbara Pistilli, Andrea Marcellusi, et al. · The Breast Journal · 7
PDF
Treatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP)
2017 · E. Cortesi, F. Cappuzzo, et al. · Annals of Oncology · 4
Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient
2015 · Marta Gubbiotti, Barbara Pistilli, et al. · Future Oncology · 4
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
2015 · Josef Thaler, Richard Greil, et al. · Annals of Oncology · 4
Mucocele-like tumour of the breast.
2003 · R Berardi, L Latini, et al. · PubMed · 4
[A case of leiomyoma of the breast].
1993 · P Manna, G M Giuseppetti, et al. · PubMed · 4
Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status
2015 · A. Sobrero, L. Latini, et al. · Annals of Oncology · 3
PDF
Works count: 45
Citation count: 1,742
H-index: 14
I10-index: 16
Year
Topic
Type